Selected therapeutic targets on AML niche
Mechanism | Targets | Cognate ligand in BM niche | BM niche | Drug | Clinical trials reference |
---|---|---|---|---|---|
Adhesion of leukemic stem cell to bone marrow niche | CD44 | Hyaluronan, osteopontin | Endosteal niche | Polymeric nanoparticle-mediated silencing of CD44 | N/R |
Selectin E | Selectin E ligand | Vascular niche | Uproleselan | [108, 109] | |
VLA4 | VCAM1 | Vascular niche | AS101 | N/R | |
CXCL12/CXCR4 axis | - | CXCR4 | Vascular niche | Ulocuplumab | [108, 109] |
Plerixafor | [119, 120] | ||||
CXCR4 antagonist LY2510924 | [121] | ||||
Angiogenesis | - | VEGF | Vascular niche | Aflibercept | N/R |
Bevacizumab | [136] | ||||
Angiopoietins | Vascular niche | Trebananib | [139] | ||
Bone remodeling signaling pathway | - | Proteasome inhibitors | Vascular niche | Bortezomib | [143] |
Carfilzomib | [144] | ||||
Ixazomib | [145] | ||||
Receptor tyrosine kinase inhibitors | Vascular niche | Cabozantinib | [146] | ||
Bone marrow adipose tissue remodeling | - | FAO inhibitors | Vascular niche | Avocatin B | N/R |
Tumor immune evasion | - | PD1 inhibitor | - | Nivolumab | [170] |
Pembrolizumab | [171, 172] | ||||
Anti-CTLA4 | - | Ipilimumab | [167] |
-: no data. N/R: no reference; VLA4: very late antigen 4; VCAM1: vascular adhesion molecule 1; VEGF: vascular endothelial growth factor; FAO: fatty acid β-oxidation; PD1: programmed death 1; CTLA4: cytotoxic T-lymphocyte associated protein 4
SK: Conceptualization, Writing—original draft, Writing—review & editing. MES and AEG: Data collection. GV: Funding acquisition. PPP: Supervision.
Pier Paolo Piccaluga is the Editorial Board Member of Exploration of Targeted Anti-tumor Therapy and Guest Editor of Mechanisms of Targeted Therapy Resistance and Reversal Strategies, but he had no involvement in the journal review process of this manuscript. The other authors declare that there is no conflict of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
The work reported in this publication was funded by the Italian Ministry of Health [RC-2023-2778976, PRIN 2022NXK38S, and FIRB Futura 2011 RBFR12D1CB]. Giuseppe Visani received the support of AIL Pesaro Onlus. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2024.